1
项与 Human Menstrual Blood-derived Mesenchymal Stem Cells(S-Evans Biosciences Co., Ltd.) 相关的临床试验Phase 1/2 Study of Human Menstrual Blood-derived Mesenchymal Stem Cells Transplantation for the Evaluation of the Efficacy and Safety in Patients With Liver Cirrhosis
Orthotopic liver transplantation (OLT) is currently the most effective method for end-stage liver diseases. However, the critical shortage of donor organs, high cost, and the problem of immune rejection limit its clinical application, and even some patients on the waiting list will never survive to receive a matched liver. Stem cell transplantation instead of conventional medical therapy or orthotopic liver transplantation will be a promising alternate approach to regenerate damaged hepatic mass. Adult mesenchymal stem cells (MSCs) are generally thought of as an autologous source of regenerative cells in previous studies.In this study, the safety and efficacy of menstrual blood-derived stem cells transplantation for patients with liver cirrhosis will be evaluated.
100 项与 Human Menstrual Blood-derived Mesenchymal Stem Cells(S-Evans Biosciences Co., Ltd.) 相关的临床结果
100 项与 Human Menstrual Blood-derived Mesenchymal Stem Cells(S-Evans Biosciences Co., Ltd.) 相关的转化医学
100 项与 Human Menstrual Blood-derived Mesenchymal Stem Cells(S-Evans Biosciences Co., Ltd.) 相关的专利(医药)
100 项与 Human Menstrual Blood-derived Mesenchymal Stem Cells(S-Evans Biosciences Co., Ltd.) 相关的药物交易